Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company is headquartered in Lexington, Massachusetts.
| Revenue (TTM) | 3,000 |
| Gross Profit (TTM) | 3,000 |
| EBITDA | $-84.77M |
| Operating Margin | 0.00% |
| Return on Equity | -778.00% |
| Return on Assets | -74.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.13 |
| Price-to-Book | 5.06 |
| Price-to-Sales (TTM) | 4489.16 |
| EV/Revenue | 14527.72 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -57.10% |
| Shares Outstanding | $13.27M |
| Float | $12.14M |
| % Insiders | 1.45% |
| % Institutions | 53.18% |
Volatility is currently contracting
Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance Transcript
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fractyl between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham
BENSALEM TOWNSHIP, Pa., Oct. 15, 2026 /PRNewswire/ -- The Law Offices of Howard G.
New class action for Fractyl (GUTS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/20/2026
Allegations focus on two public offerings in August and September 2025 that allegedly raised approximately $76.7 million in net proceeds while GUTS shares traded at prices allegedly inflated by the Company's interim Revita data. NEW YORK, Oct. 15, 2026 /PRNewswire/ -- SueWallSt alerts investors in Fractyl Health, Inc. (NASDAQ: GUTS) of a pending securities class action covering purchases between January 13, 2025 and January 29, 2026.
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ: GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fractyl between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 14, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. (""Fractyl" or the "Company") (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fractyl Health, Inc., (“Fractyl” or the "Company") (NASDAQ: GUTS) investors of a class action on behalf of investors that bought securities between January 13, 2025 - January 29, 2026, inclusive (the “Class Period”). Fractyl investors have until October 20, 2026 to file a lead plaintiff motion.
LOS ANGELES, Oct. 14, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Fractyl Health, Inc. (GUTS) have opportunity to lead the securities fraud class action lawsuit.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GUTS and any ticker you trade — then tracks every position and per-strategy win rate.
